Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company focused on discovering and developing innovative small-molecule drugs for serious diseases. The company has established itself as a leader in the treatment of cystic fibrosis with its key therapies, including Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, which are recognized as the standard of care worldwide. In addition to its cystic fibrosis portfolio, Vertex is expanding its capabilities with Casgevy, a gene-editing therapy aimed at treating beta thalassemia and sickle-cell disease. The company is also exploring small-molecule inhibitors for managing acute and chronic pain without opioids, as well as targeting APOL1-mediated kidney diseases. Vertex's ongoing research includes developing cell therapies that aim to restore functional capabilities in affected patients, reflecting its commitment to addressing a broad range of serious health challenges.

Jeffrey Leiden Ph.D

Executive Chairman

Georgia McGaughey

Vice President

15 past transactions

Arbor Biotechnologies

Series C in 2025
Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

Alpine Immune Sciences

Acquisition in 2024
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company leverages a proprietary scientific platform to transform native immune system proteins into innovative therapeutic candidates. Its leading programs include ALPN-101, a dual antagonist targeting the inducible T cell costimulator and CD28 pathways, designed for autoimmune and inflammatory conditions, and ALPN-303, a dual antagonist of the B cell activating factor and proliferation-inducing ligand, which is vital for B cell activation and survival. Additionally, Alpine Immune Sciences has established a collaboration with Kite Pharma to explore immunotherapies targeting the immune synapse for cancer treatment.

Septerna

Acquisition in 2023
Septerna is a biotechnology company focused on discovering and advancing novel small-molecule medicines that target G protein-coupled receptors (GPCRs). The company aims to improve patient outcomes by integrating innovative drug discovery technologies with GPCR drug targets. Utilizing its Native Complex platform, Septerna facilitates industrial-scale drug discovery through advanced screening technologies and structure-based drug design. This approach enables medical researchers to efficiently identify treatments for a variety of diseases.

ViaCyte

Acquisition in 2022
ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

Vectrus

Acquisition in 2022
Vectrus is a global government services company that specializes in providing facility and logistics services, as well as information technology and network communication services, primarily to U.S. government clients worldwide. The company is recognized for its operational excellence and superior program performance, which contribute to the establishment of long-term relationships with its customers. Vectrus is committed to ensuring mission success for its clients by delivering reliable and effective services tailored to meet their unique needs.

Arbor Biotechnologies

Series B in 2021
Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

Kymera Therapeutics

Series C in 2020
Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

Semma Therapeutics

Acquisition in 2019
Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Exonics Therapeutics

Acquisition in 2019
Exonics Therapeutics, Inc. is focused on developing gene editing technologies to address Duchenne muscular dystrophy (DMD), a severe genetic neuromuscular disorder. Founded in 2017 and headquartered in Boston, Massachusetts, with an additional office in Dallas, Texas, the company utilizes CRISPR/Cas9 technology in conjunction with adeno-associated virus (AAV) delivery systems. This innovative approach targets and corrects specific exon mutations that hinder the production of dystrophin, a crucial protein for muscle fiber stability and protection. By aiming for a permanent correction of these genetic mutations, Exonics Therapeutics seeks to provide patients with lasting improvements in their quality of life. The company operates as a subsidiary of Vertex Pharmaceuticals Incorporated.

Genomics

Series B in 2018
Genomics PLC, established in 2014 and headquartered in Oxford, UK, specializes in developing algorithms and software solutions that harness the power of genomics. The company focuses on cancer, microbes, and rare diseases, offering solutions that transform healthcare provisions for governments and providers, de-risk drug development for pharmaceutical clients, enhance diagnoses and treatment options for clinicians, and ensure accurate result processing for research labs and genome analysts. By applying advanced analytics to massive genomic and phenotypic datasets, Genomics PLC aims to lead the genomic transformation of healthcare, revealing the human wiring diagram and setting standards for genomic data utilization.

Genomics

Series B in 2018
Genomics PLC, established in 2014 and headquartered in Oxford, UK, specializes in developing algorithms and software solutions that harness the power of genomics. The company focuses on cancer, microbes, and rare diseases, offering solutions that transform healthcare provisions for governments and providers, de-risk drug development for pharmaceutical clients, enhance diagnoses and treatment options for clinicians, and ensure accurate result processing for research labs and genome analysts. By applying advanced analytics to massive genomic and phenotypic datasets, Genomics PLC aims to lead the genomic transformation of healthcare, revealing the human wiring diagram and setting standards for genomic data utilization.

Obsidian Therapeutics

Series A in 2017
Obsidian Therapeutics develops innovative cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Founded in 2015 and based in Cambridge, Massachusetts, the company focuses on creating next-generation therapies that utilize pharmacologic operating systems to provide precise control over protein activity within cells. This technology allows for the development of adoptive cell therapies with advanced functionalities that can be managed by physicians using simple, safe, and orally active medications. By offering improved control over treatment, Obsidian Therapeutics aims to provide better outcomes for patients compared to existing cell therapy options.

CRISPR Therapeutics

Series B in 2015
CRISPR Therapeutics AG is a biotechnology company based in Zug, Switzerland, dedicated to developing transformative gene-based medicines for serious human diseases using CRISPR/Cas9 technology. This revolutionary gene-editing platform allows for precise changes to genomic DNA. The company's portfolio includes therapeutic programs targeting hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Their lead product candidate is CTX001, a gene-edited therapy for transfusion-dependent beta thalassemia or severe sickle cell disease, which has been approved as Casgevy in collaboration with Vertex Pharmaceuticals. Additionally, CRISPR Therapeutics is developing CTX110, an allogeneic CAR-T therapy targeting CD19-positive malignancies, and other programs like CTX120 for multiple myeloma and CTX130 for solid tumors and hematologic malignancies. The company also engages in regenerative medicine programs for diabetes and genetic disease treatments such as glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. CRISPR Therapeutics has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc.

ViroChem Pharma

Acquisition in 2009
ViroChem Pharma is a privately held company focused on developing and producing pharmaceutical products for viral diseases, specifically targeting Hepatitis C (HCV) and Human Immunodeficiency Virus (HIV). The company is advancing two investigational HCV polymerase inhibitors that are currently in clinical development, aiming to provide effective treatment options for patients suffering from these viral infections. With a commitment to addressing unmet medical needs in the field of virology, ViroChem Pharma plays a critical role in the ongoing fight against these significant health challenges.

Aurora Biosciences Corporation

Acquisition in 2001
Aurora Biosciences Corporation ("Aurora" or the "Company") designs and develops proprietary drug discovery systems, services and technologies to accelerate and enhance the discovery of new medicines. Aurora is developing an integrated technology platform comprised of a portfolio of proprietary fluorescent assay technologies and an ultra-high throughput screening ("UHTS") system designed to allow assay miniaturization and to overcome many of the limitations associated with the traditional drug discovery process.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.